Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy

被引：37

作者：

Zheng, Yuan-qiang ^{[1
]}

Naguib, Youssef W. ^{[2
]}

Dong, Yixuan ^{[2
]}

Shi, Yan-chun ^{[1
]}

Bou, Shorgan ^{[3
]}

Cui, Zhengrong ^{[1
,2
]}

机构：

[1] Inner Mongolia Med Univ, Inner Mongolia Key Lab Mol Biol, Hohhot 010059, Peoples R China

[2] Univ Texas Austin, Div Pharmaceut, Coll Pharm, Austin, TX 78712 USA

[3] Inner Mongolia Univ, Natl Res Ctr Anim Transgen Biotechnol, Hohhot, Peoples R China

来源：

EXPERT REVIEW OF VACCINES | 2015年 / 14卷 / 09期

基金：

中国国家自然科学基金; 美国国家卫生研究院;

关键词：

bacterial vector; Bacillus Calmette-Guerin; bladder cancer; clinical applications; infectious disease; recombinant BCG; tumor; vaccine development; MYCOBACTERIUM-BOVIS BCG; SUPERFICIAL BLADDER-CANCER; CELL-WALL SKELETON; GAMMA-INTERFERON PRODUCTION; EXPRESSING PERTUSSIS TOXIN; APOPTOSIS-INDUCING LIGAND; CYTOTOXIC T-LYMPHOCYTES; LONG-TERM EFFICACY; CARCINOMA IN-SITU; IMMUNE-RESPONSES;

D O I：

10.1586/14760584.2015.1068124

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Bacillus Calmette-Guerin (BCG) vaccines are attenuated live strains of Mycobacterium bovis and are among the most widely used vaccines in the world. BCG is proven to be effective in preventing severe infant meningitis and miliary tuberculosis. Intravesical instillation of BCG is also a standard treatment for non-muscle invasive bladder cancer. In the past few decades, recombinant BCG (rBCG) technology had been extensively applied to develop vaccine candidates for a variety of infectious diseases, including bacterial, viral, and parasite infections, and to improve the efficacy of BCG in bladder cancer therapy. This review is intended to show the vast applications of BCG and recombinant BCG (rBCG) in the prevention of infectious diseases and cancer immunotherapy, with a special emphasis on recent approaches and trends on both pre-clinical and clinical levels.

引用

页码：1255 / 1275

页数：21

共 50 条

[1] BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY
LAMM, DL
[J]. JOURNAL OF UROLOGY, 1987, 138 (02): : 391 - 391
[2] COMPLICATIONS OF BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY
LAMM, DL
[J]. UROLOGIC CLINICS OF NORTH AMERICA, 1992, 19 (03) : 565 - 572
[3] Bacillus Calmette-Guerin Immunotherapy for Cancer
Cardillo, Fabiola
Bonfim, Maiara
da Silva Vasconcelos Sousa, Periela
Mengel, Jose
Ribeiro Castello-Branco, Luiz Roberto
Pinho, Rosa Teixeira
[J]. VACCINES, 2021, 9 (05)
[4] Calmette-Guerin in vaccine development and tumor immunotherapy
Zheng, Y.
Zhou, Y.
Chen, Y.
Jia, Y.
Shi, Y.
[J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1835 - 1835
[5] Frequency of Accelerated Bacillus Calmette-Guerin Response in Bacillus Calmette-Guerin Vaccinated Children
Irfan, Muhammad
Masood, Syed Usama
Laique, Talha
[J]. PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2021, 15 (05): : 1011 - 1013
[6] Predicting bacillus Calmette-Guerin immunotherapy effectiveness
Griffith, Thomas S.
[J]. JOURNAL OF UROLOGY, 2007, 178 (06): : 2247 - 2248
[7] A rare complication of bacillus Calmette-Guerin immunotherapy
Vandermeersch, Denis
Verroken, Alexia
Mathys, Vanessa
Pothen, Lucie
[J]. ACTA CLINICA BELGICA, 2023, 78 : 29 - 30
[8] IMMUNOTHERAPY OF PROSTATIC CARCINOMA WITH BACILLUS CALMETTE-GUERIN
MERRIN, C
HAN, T
KLEIN, E
WAJSMAN, Z
MURPHY, GP
[J]. CANCER CHEMOTHERAPY REPORTS PART 1, 1975, 59 (01): : 157 - 163
[9] Bacillus of Calmette-Guerin immunotherapy: which protocol?
Saint, Fabien
[J]. PROGRES EN UROLOGIE, 2008, 18 : S99 - S104
[10] BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY - TECHNIQUES AND RESULTS
BROSMAN, SA
[J]. UROLOGIC CLINICS OF NORTH AMERICA, 1992, 19 (03) : 557 - 564

← 1 2 3 4 5 →